MetaCytoLytics

MetaCytoLytics is a subsidiary of Viral Genetics that is focused on the development of our licensed Metabolic Disruption technology that has application in the treatment of certain diseases including drug-resistant tumors through the mechanism of manipulating how certain types of cells use or store fats and sugars to generate internal energy.

Through manipulation of tumor cells internal metabolisms, we are studying how to cause their death and are working to develop treatments for drug resistant tumors – the leading cause of death from cancer. Currently the company is working at development of a compound for the treatment of glioblastoma, a deadly form of brain cancer. A clinical trial at Scott and White Hospital under an investigator’s IND is planned for January 2011.

The compounds under study include dichloroacetic acid (DCA) and a combination of 2 deoxyglucose and etoximir. DCA has been the subject of human clinical trials by unrelated third parties. Our licensed patent rights cover the use of the compounds and the mechanisms underlying them.

We have also established a subsidiary called VG Energy to pursue the non-human applications of the MDT technology, specifically the enhancement of yields of plant oils including refinable oil from algae for biofuel.

Visit: VG Energy, Inc. to learn more.